{Reference Type}: Meta-Analysis
{Title}: Efficacy and safety of trifluridine/tipiracil (TAS-102) in patients with metastatic colorectal cancer: a systematic review and meta-analysis.
{Author}: Huang F;Yang H;Bao W;Bin Y;Zhou S;Wang M;Lv X;
{Journal}: Clin Transl Oncol
{Volume}: 26
{Issue}: 2
{Year}: 2024 Feb 7
{Factor}: 3.34
{DOI}: 10.1007/s12094-023-03268-5
{Abstract}: <B>OBJECTIVE: </B>The purpose of this meta-analysis is to evaluate the efficacy and safety of TAS-102 in treating metastatic colorectal cancer (mCRC) using the most recent data available.<BR><B>METHODS: </B>The literature on the efficacy and safety of TAS-102 versus placebo and/or best supportive care (BSC) in mCRC was obtained through a systematic search of PubMed, Embase, and Web of Science databases through January 2023. Identify the included literature and extract pertinent data, such as the overall survival (OS), progression-free survival (PFS), time to treatment failure (TTF), disease control rate (DCR), incidence of adverse events (AEs) and serious adverse events (SAEs).<BR><B>RESULTS: </B>There were eight eligible articles that included 2903 patients (1964 TAS-102 versus 939 Placebo and/or BSC). In this meta-analysis, TAS-102 treatment resulted in longer OS, PFS, TTF, and higher DCR in patients with mCRC versus placebo and/or BSC. TAS-102 improved OS and PFS in subgroup analyses of mCRC patients with KRAS wild-type and KRAS mutant-type. In addition, TAS-102 did not increase the incidence of serious adverse events.<BR><B>CONCLUSIONS: </B>TAS-102 can enhance the prognosis of mCRC patients whose standard therapy has failed, regardless of KRAS mutation status, and its safety is acceptable.